You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

CLINICAL TRIALS PROFILE FOR ZANAMIVIR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Zanamivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00540501 ↗ A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects Withdrawn GlaxoSmithKline Phase 1 2007-10-01 This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed GlaxoSmithKline Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
NCT00784784 ↗ Zanamivir Versus Trivalent Split Virus Influenza Vaccine Completed Mount Sinai Hospital, Canada Phase 3 2008-11-01 This unblinded pilot study is intended to assess the feasibility of a larger double-blind, randomized control trial. For the larger trial the investigators are interested in understanding the relative benefits of vaccine and antiviral prophylaxis, the risk factors for influenza infection in healthy adults, and in assessing the safety and tolerability of seasonal antiviral prophylaxis in healthcare workers. The pilot study will be assessing the rate of infection with influenza and the rate of adherence to long-term zanamivir in 60 healthy volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zanamivir

Condition Name

Condition Name for Zanamivir
Intervention Trials
Influenza, Human 11
Influenza 10
Bioequivalence 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zanamivir
Intervention Trials
Influenza, Human 23
Infections 5
Infection 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zanamivir

Trials by Country

Trials by Country for Zanamivir
Location Trials
United States 113
Australia 14
Canada 14
China 11
Thailand 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zanamivir
Location Trials
Texas 6
Pennsylvania 5
New York 5
Missouri 5
Kentucky 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zanamivir

Clinical Trial Phase

Clinical Trial Phase for Zanamivir
Clinical Trial Phase Trials
Phase 4 3
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zanamivir
Clinical Trial Phase Trials
Completed 22
Not yet recruiting 3
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zanamivir

Sponsor Name

Sponsor Name for Zanamivir
Sponsor Trials
GlaxoSmithKline 13
Novagenix Bioanalytical Drug R&D Center 5
Farmagen Ar-Ge Biyot. Ltd. Sti 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zanamivir
Sponsor Trials
Other 37
Industry 21
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Zanamivir: Clinical Trials, Market Analysis, and Projections

Introduction

Zanamivir, an antiviral drug targeting the neuraminidase active site of influenza viruses, has been a significant player in the treatment and prophylaxis of influenza A and B. Here, we delve into the recent clinical trials, market analysis, and future projections for zanamivir.

Clinical Trials Overview

Phase III Trials

The most recent and pivotal clinical trials for intravenous (IV) zanamivir involved a randomized, double-blind, double-dummy Phase III study. This study aimed to compare the efficacy and safety of IV zanamivir (300 mg or 600 mg twice daily) against oral oseltamivir (75 mg twice daily) in hospitalized adults and adolescents with influenza[1].

Key points from these trials include:

  • Efficacy and Safety: The trials focused on primary endpoints such as time to clinical response and secondary endpoints like time to respiratory status improvement. Despite the trials, IV zanamivir did not meet its pre-specified primary endpoint of superiority over oral oseltamivir[1].
  • Resistance and Subpopulations: The studies also addressed the issue of resistance, with one resistance substitution detected in an immunocompromised adult. There was a discussion on the possibility of granting marketing authorization in pre-specified subpopulations where a clear benefit was shown, even if the overall study did not demonstrate superiority[1].

Extrapolation to Pediatric Patients

Scientific advice from the European Medicines Agency (EMA) in 2012 and 2014 focused on the extrapolation of efficacy results from hospitalized adults and older adolescents to pediatric patients, including neonates. This involved retrospective chart reviews of pediatric patients treated with IV zanamivir under compassionate use programs[1].

Post-Authorization Studies

Post-authorization studies were proposed to evaluate the clinical effectiveness of IV zanamivir in subjects hospitalized in intensive care units (ICUs) with drug-resistant influenza. These studies are crucial for understanding the drug's performance in real-world settings and managing risks associated with its use[1].

Market Analysis

Global Market Size and Forecast

The global market for zanamivir is relatively small but growing. As of 2023, the market was estimated to be worth US$10 million and is forecasted to reach US$14 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 4.5% during the period 2024-2030[2].

Key Players

The market for zanamivir is dominated by several key players, including Merck, Tokyo Chemical Industry (TCI), DC Chemicals, Hairui Chemical, Key Organics, BioCrick, BLD Pharmatech, BOC Sciences, CSNpharm, Selleck Chemicals, and Glentham Life Sciences[2].

Applications and Types

Zanamivir is used primarily in the pharmaceutical and scientific research sectors. The market report segments zanamivir by type, including purity levels of 97%, 98%, and 99%, among others[2].

Market Trends and Projections

Influenza Medication Market

The global influenza medication market, which includes zanamivir, oseltamivir, peramivir, and other antivirals, was valued at US$1.69 billion in 2016 and is projected to reach US$2.01 billion by 2025, growing at a CAGR of 1.40% during the period from 2017 to 2025. Oseltamivir currently leads this market, but zanamivir remains a significant player[5].

Regional Dominance

North America and Europe are expected to remain dominant in the influenza medication market, including zanamivir, due to advanced healthcare infrastructure and higher adoption rates of antiviral medications[5].

Challenges and Opportunities

Clinical Efficacy and Resistance

One of the main challenges for zanamivir is demonstrating superiority over existing treatments like oseltamivir. The drug's efficacy, particularly in pediatric patients and against drug-resistant strains, remains a focus area for ongoing and future studies[1][4].

Regulatory Pathways

The EMA's consideration of alternative regulatory routes, such as conditional marketing authorization or exceptional circumstances, highlights the potential for zanamivir to be approved even if it does not meet all traditional efficacy criteria. This could provide a pathway for the drug to reach the market sooner, especially in subpopulations where it shows clear benefits[1].

Key Takeaways

  • Clinical Trials: IV zanamivir has undergone extensive Phase III trials, though it did not demonstrate superiority over oral oseltamivir. Ongoing studies focus on its use in ICUs and pediatric patients.
  • Market Size and Growth: The global zanamivir market is forecasted to grow from US$10 million in 2023 to US$14 million by 2030, with a CAGR of 4.5%.
  • Key Players: The market is dominated by several pharmaceutical and chemical companies.
  • Applications: Zanamivir is primarily used in pharmaceutical and scientific research sectors.
  • Market Trends: North America and Europe are expected to remain dominant in the influenza medication market.

FAQs

What is the current market size of zanamivir and its projected growth?

The global market for zanamivir was estimated to be worth US$10 million in 2023 and is forecasted to reach US$14 million by 2030, growing at a CAGR of 4.5% during the period 2024-2030[2].

Which companies are the main players in the zanamivir market?

The main players include Merck, Tokyo Chemical Industry (TCI), DC Chemicals, Hairui Chemical, Key Organics, BioCrick, BLD Pharmatech, BOC Sciences, CSNpharm, Selleck Chemicals, and Glentham Life Sciences[2].

What are the primary applications of zanamivir?

Zanamivir is primarily used in the pharmaceutical and scientific research sectors[2].

How does zanamivir compare to other influenza antivirals in clinical efficacy?

Zanamivir has shown efficacy in reducing the duration of illness in adults but has not demonstrated significant improvement in children. It did not meet its primary endpoint of superiority over oral oseltamivir in recent Phase III trials[1][4].

What are the regulatory challenges and opportunities for zanamivir?

Zanamivir faces challenges in demonstrating superiority over existing treatments, but alternative regulatory pathways such as conditional marketing authorization or exceptional circumstances could provide opportunities for its approval, especially in specific subpopulations[1].

Sources

  1. European Medicines Agency. Dectova, INN-zanamivir - European Medicines Agency. [PDF] EMA, 2019.
  2. Valuates Reports. Zanamivir - Global Market Share and Ranking, Overall Sales and Forecast.
  3. BioSpace. U.S. Clinical Trials Market Size Industry Analysis Report, 2033.
  4. mBio. The current state of research on influenza antiviral drug.
  5. BioSpace. Influenza Medication Market: North America and Europe to Remain Dominant.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.